MDL | - |
---|---|
Molecular Weight | 627.96 |
Molecular Formula | C34H65N3O5S |
SMILES | C[C@@]12[C@](C[C@@H](O)[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@]4([H])[C@@H](CC[C@H](C(C)C)OS(=O)(O)=O)C)([H])C[C@@H](NCCCNCCCCN)CC1 |
Squalamine(MSI-1256) is an aminosterol compound with potent broad spectrum antiviral activity. IC50 value: Target: in vitro: squalamine can strongly displace membrane-bound cationic proteins such as Rac1, a ρ-GTPase recruited to the inner leaflet of the eukaryotic cytoplasmic membrane for the actin remodeling necessary for endocytosis. At concentrations between 20 and 60 μg/mL, squalamine has been shown to inhibit a broad array of growth factor-induced, actin-dependent responses in endothelial cells, including cell migration, cell division, and vascular tube formation in a 3D matrix [1]. Squalamine effectively inhibited HBV replication in human primary hepatocytes when added either during the initial exposure of virus to the cells or at 24 h after infection . A similar study was performed to evaluate the effect of squalamine on the replication of HDV. Squalamine was introduced at 20 μg/mL during HDV exposure, and the effects were measured at day 7 when total RNA was extracted and assayed for HDV RNA sequences [1]. in vivo: one time daily treatment with squalamine (15 or 30 mg/kg per d s.c.) was started beginning on day 1 or 2 after viral administration and continuing until day 8 or 9, respectively. Survival was monitored, and animals that remained alive by day 21 were considered cured [1].
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT00139282 | Genaera Corporation |
Wet Age-Related Macular Degeneration
|
June 2005 | Phase 3 |
NCT02614937 | Ohr Pharmaceutical Inc.|Cumberland Valley Retina Consultants, PC |
Retinal Vein Occlusion|Macular Edema
|
April 2013 | Phase 1|Phase 2 |
NCT00333476 | Genaera Corporation |
Macular Degeneration
|
May 2006 | Phase 2 |
NCT00089830 | Genaera Corporation |
Macular Degeneration
|
August 2004 | Phase 2 |
NCT02349516 | Starr Muscle|Ohr Pharmaceutical Inc.|Prism Vision Group |
Diabetic Retinopathy
|
February 2015 | Phase 2 |
NCT01678963 | Ohr Pharmaceutical Inc. |
Neovascular Age Related Macular Degeneration
|
November 2012 | Phase 2 |
NCT00244920 | OHSU Knight Cancer Institute|National Cancer Institute (NCI) |
Prostate Cancer
|
January 2002 | Phase 2 |
NCT01769183 | Elman Retina Group |
Retinal Neovascularization
|
February 2013 | Phase 2 |
NCT00094120 | Genaera Corporation |
Macular Degeneration
|
October 2004 | Phase 2 |
NCT02727881 | Ohr Pharmaceutical Inc. |
Age-related Macular Degeneration
|
April 12, 2016 | Phase 3 |
NCT00021385 | Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) |
Ovarian Cancer
|
May 2001 | Phase 2 |
NCT02511613 | Ohr Pharmaceutical Inc. |
Age-Related Macular Degeneration
|
July 2015 | Phase 2 |
Solid
Squalus acanthias
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : 100 mg/mL ( 159.25 mM ; Need ultrasonic)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 1.5925 mL | 7.9623 mL | 15.9246 mL |
5 mM | 0.3185 mL | 1.5925 mL | 3.1849 mL |
10 mM | 0.1592 mL | 0.7962 mL | 1.5925 mL |